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Background: Women with polycystic ovary syndrome (PCOS) have higher risk for cardiovascular disease (CVD).
Heart type fatty acid binding protein (HFABP) has been found to be predictive for myocardial ischemia.Wet ested
whether HFABP is the predictor for CVD in PCOS patients, who have an increased risk of cardiovascular disease.
Methods: This was a prospective, cross sectional controlled study conducted in a training and research hospital.The
study population consisted of 46 reproductive-age PCOS women and 28 control subjects. We evaluated
anthropometric and metabolic parameters, carotid intima media thickness and HFABP levels in both PCOS patients
and control group.
Results: Mean fasting insulin, homeostasis model assessment insulin resistance index (HOMA-IR), triglyceride, total
cholesterol, low density lipoprotein cholesterol, free testosterone, total testosterone, carotid intima media thickness
(CIMT) levels were significantly higher in PCOS patients. Although HFABP levels were higher in PCOS patients, the
difference did not reach statistically significant in early age groups. After adjustment for age and body mass index,
HFABP level was positive correlated with hsCRP, free testosterone levels, CIMT and HOMA-IR.
Conclusions: Heart type free fatty acid binding protein appeared to have an important role in metabolic response
and subsequent development of atherosclerosis in insulin resistant, hyperandrogenemic PCOS patients.
Keywords: Polycystic ovary syndrome, Heart type free fatty acid binding protein, Carotid intima media thickness,
Insulin resistance, Cardiovascular disease riskIntroduction
Polycystic ovary syndrome (PCOS) is a common endo-
crine disorder affecting at least five to10% of women of
reproductive age [1]. Polycystic ovary syndrome is char-
acterized by hyperandrogenism, menstrual disturbance,
anovulation, infertility and obesity [2], and also asso-
ciated with an increased number of cardiovascular risk
factors [3], and early atherosclerosis [4,5]. Hyperinsulin-
ism and insulin resistance are frequent findings in PCOS* Correspondence: mustafaozbek10@hotmail.com
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reproduction in any medium, provided the orpatients, and these traits have cause-consequence rela-
tionships with low-grade chronic inflammation [6], and
increased cardiovascular disease (CVD) risk [7].
Heart-type fatty acid-binding protein (H-FABP) is a
low molecular-weight cytoplasmic protein that is abun-
dant in the myocardium, and provides intracelluler up-
take of free fatty acid protein [8].
Several studies have assessed free fatty acid binding pro-
tein (FABP) and shown to positively correlated with cardio-
metabolic risk factors [9-11], but heart type free acid binding
protein has not been evaluated in PCOS patients, yet.
The aim of this study was to evaluate the H-FABP in
PCOS patients and its association between cardiometa-
bolic factors.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We studied 46 patients with PCOS and age- body mass
index (BMI) matched 28 healthy controls consisting of
women with regular ovulatory cycles and normal andro-
gen levels. All patients gave a written consent. All
patients were female and nonsmokers.
The diagnosis of PCOS was made according to the Rot-
terdam European Society for Human reproduction and
Embryology/ American Society for Reproductive Medi-
cine–sponsored PCOS Consensus Workshop Group [12].
The revised diagnostic criteria of PCOS is as follows, with
at least two of the following being required;
1. Oligo and/or anovulation that is menstrual
disturbance
2. Clinical and/or biochemical signs of
hyperandrogenism
3. Polycystic ovarian appearance on ultrasound
Participants who had smoking history, diabetes melli-
tus, hyperprolactinemia, congenital adrenal hyperplasia,
androgen-secreting tumours, thyroid disorders, Cushing
syndrome (1 mg dexamethasone suppression test), infec-
tion diseases, hypertension, hepatic or renal dysfunction
were excluded from the study. Patients were also excluded
if they had used within 3 months before enrollment con-
founding medications, including oral contraceptive agents,
antilipidemic drugs, hypertensive medications, and
insulin-sensitizing drugs.
Control group (n = 28) consisted of healthy patients
who were admitted to check-up unit without any systemic
disorder. All of the women in the control group had hir-
sutism score <8. All women in the control group had
regular menses, every 21–35 days. None of the women in
the control group had polycystic ovary in ultrasound.
Weight and height were measured in light clothing
without shoes. BMI was calculated, dividing the weight
divided by square of height (kg/m2). Waist circumfer-
ence was measured at the narrowest level between the
costal margin and iliac crest, and the hip circumference
was measured at the widest level over the buttocks while
the subjects were standing and breathing normally. The
waist-to-hip ratio (WHR) was calculated.
The degree of hirsutism was determined by Ferriman-
Gallwey (FG) scoring [13]. The BMI, WHR and hirsut-
ism scores were assessed by a single investigator for all
of the subjects.
Measurement of carotid intima media thickness
Carotid intima media thickness (CIMT) was derived
from noninvasive ultrasound of the common carotid ar-
teries, using a high-resolution ultrasound machine
(Sonoline G 40, Siemens) with 7.5 MHz mechanical sec-
tor transducer. The intima media thickness was definedas the distance between the blood-intima and media-
adventitia boundaries on B-mode imaging.
Biochemical evaluation
Venous blood samples were obtained in the follicular
phase of a spontaneous or progesterone induced men-
strual cycle. Before the study, blood samples were drawn
from each patient after 12 h overnight fasting for the de-
termination of hormones, lipid profile, high-sensitive C-
reactive protein (hs-CRP), insulin levels, glucose levels.
Plasma glucose was determined with glucose oxidase/
peroxidase method (Gordion Diagnostic, Ankara, Turkey).
Serum levels of follicle-stimulating hormone (FSH),
luteinizing hormone (LH), prolactin, dehydroepiandros-
terone sulfate (DHEAS), total testosterone (T), insulin
and thyroid stimulating hormone (TSH) were measured
with specific electrochemiluminescence immunoassays
(Elecsys 2010 Cobas, Roche Diagnostics, Mannheim,
Germany). Serum 17 hydroxyprogesterone was mea-
sured by radioimmunoassay. Levels of total-cholesterol,
high density lipoprotein cholesterol (HDL-C), and tri-
glyceride (TG) were determined with enzymatic colori-
metric assays by spectrophotometry (BioSystems S.A.,
Barcelona, Spain). Low density lipoprotein cholesterol
(LDL-C) was calculated using the Friedewald formula.
Serum hs-CRP was determined using high-sensitive
CRP immunonephelometry (BN, Dade-Behring; Marburg,
Germany). The cut off for hsCRP was taken 1.5 [14].
Insulin resistance was calculated by using the homeosta-
sis model assessment insulin resistance index (HOMA-IR)
[15], according to the formula, fasting plasma glucose
(mmol/L) x fasting serum insulin (mU/mL) /22.5. The cut
off value was taken 2.7 for HOMA-IR [16].
Heart-type fatty acid binding protein
The human H-FABP ELISA is a ready-to-use solidphase
enzyme-linked immunosorbent assay based on the sand-
wich principle. Samples and standards are incubated to-
gether with peroxidase-conjugated second antibody in
microtiter wells coated with antibodies recognizing
human H-FABP. During incubation human H-FABP is
captured by the solid bound antibody. The secondary anti-
bodies will bind to the captured human H-FABP. The per-
oxidase conjugated antibody will react with the substrate,
tetramethylbenzidine (TMB). The enzyme reaction is
stopped by the addition of oxalic acid. The absorbance at
450 nm is measured with a spectrophotometer.
Statistical analyses
Collected data was entered to SPSS version 17. Continu-
ous data were shown as mean ± SD. Chi-squared tests
were used to compare differences in rates. Normally dis-
tributed variables were compared by using Student T test.
Data that were not normally distributed, as determined
Table 1 The clinical and biochemical / hormonal data in
women with polycystic ovary syndrome (PCOS) patients
and healthy controls





Age, years 21.97 ± 4.19 23.42 ± 4.70 0.17
BMI, kg/m2 24.50 ± 5.51 23.77 ± 4.91 0.56






91.23 ± 8.24 89.07 ± 9.85 0.31
HOMA-IR 3.21(0.38-12.25) 2.23(0.47-6.43) 0.011
Total cholesterol,
mg/dl
173.63 ± 29.41 154.46 ± 26.74 0.006
Triglyceride, mg/dl 111.65 ± 52.80 78.53 ± 30.30 0.002
HDL-C, mg/dl 51.47 ± 12.36 50.78 ± 11.68 0.81
LDL-C, mg/dl 99.68 ± 26.60 87.62 ± 22.58 0.04
hsCRP, mg/L 1.33(0.15-15.8) 0.97(0.15-9) 0.35
TSH, μ IU/ml 2.19 ± 0.96 1.72 ± 0.81 0,03
FSH, m IU/ml 5.49 ± 1.71 5.98 ± 1.86 0.25
LH, m IU/ml 5.69 ± 1.84 5.63 ± 2.25 0.90
Estradiol, pg/ml 40.68 ± 23.25 71.12 ± 42.00 <0.001
Free testosterone,
pg/ml
2.99 ± 1.09 1.58 ± 0.51 <0.001
Total testosterone,
ng/ml
0.56 ± 0.27 0.41 ± 0.14 0.01
17-OHprogesterone,
ng/ml
1.45 ± 0.60 0.98 ± 0.57 0.002
DHEAS, μq/dl 292.60 ± 138.54 175.28 ± 81.63 <0.001
CIMT, mm 0.42 ± 0.056 0.37 ± 0.061 <0,001
HFABP, ng/dl 39.87(22.88-135.12) 35.64(17.86- 79.97) 0.419
BMI body mass index, HOMA-IR homeostasis model assessment insulin
resistance index, HDL-C high density lipoprotein cholesterol, LDL-C LOW
density lipoprotein cholesterol, hs-CRP high-sensitive C- reactive protein, TSH
thyroid stimulating hormone, FSH follicle-stimulating hormone, LH luteinizing
hormone, DHEAS dehydroepiandrosterone sulfate, CIMT carotid intima media
thickness, HFABP heart fatty acid binding protein.
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transformed before analysis. Data are expressed as mean
± SD or median with interquartile range as appropriate.
Degree of association between continuous variables was
calculated by Pearson correlation coefficient, nonnormally
distributed variables was evaluated by spearman’s rho cor-
relation coefficient. The multiple linear regression enter
method was used to determine the independent predic-
tors. Binary logistic regression analysis was used to calcu-
late odds ratio and roc curve analysis was used to
determine cut off value for HFABP with optimal sensitiv-
ity and specificity. Univariate analyses were used to adjust
HFABP with respect to age, BMI.
p value lower than 0.05 was accepted as statistically
significant.
Results
Clinical and endocrinological parameters screened in
patients with PCOS and in healthy control subjects were
shown in Table 1. We studied 46 PCOS patients (21.97 ±
4.99 mean age, range 18–33 years; BMI; 24.5 ± 5.51 kg /m2)
and 28 age and BMI matched healthy control group
(23.42 ± 4.7 mean age, range 18–32 years, BMI;
23.77 ± 4.71 kg/m2).
Mean fasting insulin, HOMA-IR, triglyceride, total
cholesterol, LDL-C, free testosterone, total testosterone,
17 OH progesterone, DHEAS, CIMT levels were signifi-
cantly higher and estradiol were significantly lower in
PCOS patients (p < 0.05) (Table 1).
Mean HFABP level was 42.40 ± 19.08 ng/dl in PCOS
patients while mean HFABP level was 40.52 ± 17.43 ng/
dl in healthy control women (p < 0.67). Although mean
HFABP level was higher in PCOS patients the difference
did not reach statistical significance. After adjustment
for age and BMI, HFABP level was positive correlated
with FG score, fasting glucose, fasting insulin, TG, TSH,
hsCRP, DHEAS, free testosterone levels, CIMT, HOMA-
IR and negative correlated with HDL-C and estradiol
levels (Table 2). In multiple linear regression analyses
logarithmic transformed HFABP was found to be sig-
nificantly associated with CIMT (beta coefficient = 0.389,
p = 0.002) (age, BMI were included in the model). The
correlation between log transformed HFABP and CIMT
was shown in Figure 1.
Mean CIMT level was 0.42 ± 0.056 millimeter in PCOS
patients while mean CIMT level was 0.37 ± 0.061 milli-
meter in healthy control women (p < 0.001). A signifi-
cant positive correlation was found between HFABP,
BMI, FG, fasting glucose, triglyceride, PRL, free testos-
terone, HOMA-IR, fasting insulin, hs-CRP and CIMT
measurement (Table 3).
In ROC curve analysis HOMA-IR ≥2.7 can be pre-
dicted by the use of HFABP at a cut off value of 37.51
with 65%sensitivity and 61% specificity (area under curve0.654, 95% confidence interval 0.52 to 0.78, p = 0.022)
(Figure 2). In binary logistic regression analyses
HFABP level higher than 37.51 ng/dl was risk
factor for higher HOMA-IR index (OR: 3,022 95%
CI(1,17-7,79), p = 0.022).
There were 29 (63%) patients with high HOMA-IR in
PCOS group, 9 (32.1%) in control (p = 0.01); 26(56.5%)
patients had high hsCRP levels in PCOS group, 12
(42.9%) in control (p = 0.254).
The participants were divided into 2 groups according
to hsCRP levels. The participants whose hsCRP levels
higher than 1.5 mg/L had higher HFABP levels but this
difference did not reach statistically significance. Also,
HFABP levels were higher in group with high FG score
(FG score ≥8). Heart type FABP protein was found
Table 2 Correlation of Age and BMI Adjusted HFABP
levels with cardiometabolic parameters
Variable r P
FG** 0.341 0.003
Fasting glucose** 0.333 0.004





Free Testosterone* 0.232 0.047
Estradiol* −0.257 0.027
TSH** 0.335 0.003
CIMT** 0.468 < 0.001
hsCRP** 0.494 a <0.001
r indicates Spearman’s rho correlation coefficient; *Correlation is significant at
the 0.05 level. **Correlation is significant at the 0.01 level. a log transformed.
HFABP heart fatty acid binding protein, FG Ferriman Gallwey Score, HOMA
homeostasis model assessment insulin resistance index, TG triglyceride, HDL-C
High density lipoprotein cholesterol, DHEAS dehydroepiandrosterone sulfate,
TSH thyroid stimulating hormone, CIMT Carotid intima media thickness, hsCRP
high sensitivity C-reactive protein.
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HOMA-IR group (Table 4).
Discussion
The results of this study demonstrate that the mean H-
FABP level was similar in early age of PCOS patients
and control group. Heart type FABP showed significant
correlations with cardiometabolic parameters independ-
ent of age and obesity.Figure 1 Correlation between log transformed H-FABP and carotid inIn recent substudy of the Women’s Ischemia Evalu-
ation Study (WISE) (14) shown that women with PCOS
have a larger number of cardiovascular events. In this
study, CVD was positively correlated with free testoster-
one. In addition, the event free survival (including fatal
and nonfatal events) was significantly lower in PCOS
compared with non-PCOS women. In our study cardio-
metabolic parameters including HOMA-IR, TG, LDL-C,
free testosterone, DHEAS, CIMT were significantly
higher in PCOS patients and positively correlated with
HFABP. Also, FG that reflects androgen effects was posi-
tively correlated with HFABP and CIMT.
In Victor et al. study an association was found be-
tween insulin resistance and an impaired endothelial
and mitochondrial oxidative metabolism. They con-
cluded that the inflammatory state related to insulin re-
sistance in PCOS affects endothelial function [17]. In
presented study hsCRP and insulin resistance were
found positive correlated with CIMT consistent with
this hypothesis.
The HFABP isoform is produced by cardiomyocytes,
skeletal muscle [18], kidney distaltubular cells [19], and
specific parts of the brain [20]. Free acid binding protein
provides intracellular translocation of long-chain fatty
acids [21]. Heart type FABP contributes signal transduc-
tion pathways [22], and is protective for cardiac myo-
cytes against the high concentrations of long-chain fatty
acids [21,23].
The plasma concentration of HFABP is influenced by
a variety of factors such as cytosolic enzymes, subcellular
location, molecular mass and concentration gradients.
Additionally, plasma clearance of FABP also affects thetima media thickness.
Table 3 Correlation of Carotid Intima Media Thickness
with Cardiometabolic Parameters
Variable r P
BMI ** 0.408 < 0.001
FG** 0.390 0.001
Fasting glucose* 0.283 0.014
Fasting insulin* 0.267 0.021
HOMA* 0.294 0.011
TG** 0.316 0.006
Free Testosterone* 0.246 0.035
HFABP** 0.396 <0.001
hsCRP* 0.293 0.011
r indicates Pearson correlation coefficient, BMI body mass index, FG ferriman
gallwey score, HOMA homeostasis model assessment insulin resistance index,
TG triglyceride, HFABP heart fatty acid binding protein, hsCRP high sensitivity
C-reactive protein.
*Correlation is significant at the 0.05 level. **Correlation is significant at the
0.01 level.
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of its smaller size, FABP pass through the glomerular
membranes and is reabsorbed and metabolized in tubu-
lar epithelial cells [24]. So, the impaired clearance due to
renal failure can cause falsely increased plasma concen-
trations, on contrary hypermetabolic states can cause
falsely decreased levels of FABP [25].
The hypothesis suggest that the release of HFABP is a
metabolically controlled property of cell membranes due
to reversible disturbance of cell metabolism [26].
Increased plasma H-FABP concentrations significantlyFigure 2 The predictive performance of heart type free fatty acid bin
resistance index according to the receiver operating characteristic (RO
95% confidence interval.correlated with increased cardiac event rates and cardiac
mortality [27,28].
A growing evidence has been found that adipocyte
type FABP (AFABP) has an great role in atherosclerotic
process and metabolic risk factors [9,29-32]. A popula-
tion based study on long-term follow-up, subjects with
higher baseline AFABP levels had progressively worse
cardiometabolic risk profile and increasing risk of the
MetS [10].
A-FABP has been found predictive for MetS even after
adjustment for its individual components whereas there
are still few studies on the association between cardio-
metabolic parameters and HFABP.
Heart type FABP has been shown to be a more sensi-
tive early marker for identification of acute myocardial
injury [33,34]. In recent study HFABP has been found
significantly higher in patients with acromegaly than in
control subjects [35]. In another study H-FABP levels
were also found significantly higher in patients with
MetS than in control subject [11]. In Yan et al. study
HFABP has been found a useful marker for illustrate
organ dysfunction and leptin has been shown to reduce
sepsis-induced organ injuries by restraining HFABP tis-
sue levels in the mouse model of sepsis [36]. However, in
PCOS patients HFABP level has not been evaluated, yet.
In our study we evaluated HFABP level in PCOS patients
and we observed PCOS patients had higher HFABP level
but the difference did not reach statistically significance in
our early age group. Additionally, we obtained positive
correlation between HFABP and CIMT.ding protein for high homeostasis model assessment –insulin
C) curve. AUC; area under the sensitivity-specificity curve, 95% CI;
Table 4 The comparison of CIMT and HFABP in FG,
HOMA, hsCRP groups
Variable CIMT Mean ± SD P HFABP Median(Min-Max) P
FG
<8 0.38 ± 0.06 0.006 35.64(17.8-135.1) 0.232
≥8 0.42 ± 0.05 41.9(22.8-85.0)
HOMA
<2.7 0.38 ± 0.05 <0.001 35.03(23.1-70.2) 0.022
≥2.7 0.43 ± 0.06 43.88(22.8-135.1)
hsCRP
<1.5 0.38 ± 0.05 0.001 35.03(17.8-71.3) 0.071
≥1.5 0.43 ± 0.06 41.78(22.8-135.1)
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ing cardiometabolic risk in potential diseases. In early age
of PCOS patients the HFABP levels are similar to control,
it is thought to be due to high metabolic rate and short
disease duration in early age group. However its higher
level has been found to associated with inflammation and
cardiometabolic risk. Therefore H-FABP seems to be a
marker that will enable the detection of cardiac injury in
advancing age PCOS patients at an early stage.
Heart type FABP appeared to have an important role
in metabolic response and subsequent development of
atherosclerosis in insulin resistant, hyperandrogenemic
PCOS patients.
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